Výsledky vyhledávání - Katja Weisel

Upřesnit hledání
  1. 1
    OP9 Stroma Augments Survival of Hematopoietic Precursors and Progenitors During Hematopoietic Differentiation from Human Embryonic Stem Cells

    OP9 Stroma Augments Survival of Hematopoietic Precursors and Progenitors During Hematopoietic Differentiation from Human Embryonic Stem Cells Autor Junfeng Ji, Kausalia Vijayaragavan, Marc Bossé, Katja Weisel, Mickie Bhatia

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

    Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma Autor Jakub Radocha, Niels W.C.J. van de Donk, Katja Weisel

    Vydáno 2021
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial

    European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial Autor Colin A. Hutchison, Mark Cook, Nils Heyne, Katja Weisel, Lucinda Billingham, A.R. Bradwell, Paul Cockwell

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany

    T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany Autor Paymon Ahmadi, Winfried Alsdorf, Lisa Leypoldt, Ricardo Kosch, Christoph Schaefers, Nico Gagelmann, Francis Ayuk, Florian Kron, Katja Weisel

    Vydáno 2025
    Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg

    Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg Autor Katja Weisel, Andrea Morgner-Miehlke, Cordula Petersen, Walter Fiedler, Andreas Block, Philippe Schafhausen, Johannes K.‐M. Knobloch, Carsten Bokemeyer

    Vydáno 2020
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence

    Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence Autor Monique Hartley-Brown, Katja Weisel, Jacopo Bitetti, John A. Carter, Simon McNamara, Molly Purser, Antonio Palumbo, Paul G. Richardson

    Vydáno 2024
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit

    Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit Autor Panagiotis Karagiannis, Felix Klingler, Viktor Arelin, Winfried Alsdorf, Christina König, Kevin Roedl, Walter Fiedler, Katja Weisel, Stefan Kluge, Carsten Bokemeyer, Dominic Wichmann

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development Autor Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios Α. Dimopoulos, Sagar Lonial

    Vydáno 2025
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study Autor Saad Z. Usmani, Hang Quach, María‐Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Xiaomei Shu, Chuang Li, Meletios Α. Dimopoulos

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

    Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis... Autor Saad Z. Usmani, Hang Quach, María‐Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten‐Kumeli, Meletios Α. Dimopoulos

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

    Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the random... Autor Meletios Α. Dimopoulos, Sagar Lonial, Keith A. Betts, Clara Chen, Miriam L. Zichlin, Alexander Brun, James Signorovitch, Dinara Makenbaeva, Sabeen Mekan, Oumar Sy, Katja Weisel, Paul G. Richardson

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

    High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial Autor Colin A. Hutchison, Paul Cockwell, V. V. Moroz, A.R. Bradwell, Lesley Fifer, Julian D. Gillmore, Mark Jesky, Markus Storr, Julie Wessels, Christopher G. Winearls, Katja Weisel, Nils Heyne, Mark Cook

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIMISMM</scp> Trial

    Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIM... Autor Paul G. Richardson, Meral Beksaç, Albert Oriol, Jindriska Lindsay, Fredrik Schjesvold, Mónica Galli, Münci Yağcı, Alessandra Larocca, Katja Weisel, Xin Yu, Cynthia Donahue, Jorge Acosta‐Reyes, Teresa Peluso, Meletios Α. Dimopoulos

    Vydáno 2025
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

    P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD)... Autor Vânia Hungria, Katja Weisel, Brooke M. Currie, Sue Perera, Neal Sule, Wei He, Astrid McKeown, Sandhya Sapra, Linda Nelsen, Mary Li, Sophie Barale, Julia Boyle, Kaytlyn McPoyle, Meletios Α. Dimopoulos

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

    The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy Autor Simon Walz, Juliane S. Stickel, Daniel J. Kowalewski, Heiko Schuster, Katja Weisel, Linus Backert, Stefan Kahn, Annika Nelde, Tatjana Stroh, Martin Handel, Oliver Kohlbacher, Lothar Kanz, Helmut R. Salih, Hans‐Georg Rammensee, Stefan Stevanović

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

    MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexam... Autor Vânia Hungria, Katja Weisel, Brooke M. Currie, Sue Perera, Neal Sule, Wei He, Katherine Davy, Astrid McKeown, Sandhya Sapra, Linda Nelsen, Mary Li, Sophie Barale, Julia Boyle, Kaytlyn McPoyle, Meletios Α. Dimopoulos

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    POSTER: MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

    POSTER: MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Do... Autor Vânia Hungria, Katja Weisel, Brooke M. Currie, Sue Perera, Neal Sule, Wei He, Katherine Davy, Astrid McKeown, Sandhya Sapra, Linda Nelsen, Mary Li, Sophie Barale, Julia Boyle, Kaytlyn McPoyle, Meletios Α. Dimopoulos

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

    Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life Autor Evangelos Terpos, Joseph Mıkhael, Roman Hájek, Ajai Chari, Sonja Zweegman, Hans C. Lee, María‐Victoria Mateos, Alessandra Larocca, Karthik Ramasamy, Martin Kaiser, Gordon Cook, Katja Weisel, Caitlin Costello, Jennifer Elliott, Antonio Palumbo, Saad Z. Usmani

    Vydáno 2021
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  19. 19
    PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULT... Autor Katja Weisel, Vânia Hungria, Hang Quach, Sung‐Soo Yoon, Paula Rodríguez‐Otero, Glenn S. Kroog, Arijit Sinha, Anita Boyapati, Charlotte Lyon, Karen Rodriguez Lorenc, Timothy J. Inocencio, James Harnett, Lei Chi, Vygngley Moore, Peter M. Voorhees

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

    Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes Autor Xavier Leleu, Thomas G. Martin, Katja Weisel, Fredrik Schjesvold, Shinsuke Iida, Fabio Malavasi, Salomon Manier, Chang‐Ki Min, Enrique M. Ocio, Charlotte Pawlyn, Aurore Perrot, Hang Quach, Joshua Richter, Ivan Špıčka, Kwee Yong, Paul G. Richardson

    Vydáno 2022
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: